The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Financial Highlights for the Second Quarter of Fiscal 2025 Biomerica continued to deliver improved financial performance, demonstrating revenue growth, disciplined cost management, and progress toward ...

NeurAxis's robust sales growth and disciplined cost management have set the stage for achieving cash flow breakeven in 2026. Notably, recent investments from life science-focused funds have bolstered ...

A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral ...

Drugs aren't always the best way to manage symptomsBy Sally WadykaAbout 10 to 15 percent of adults in the U.S. have irritable ...